DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics... Show more
DVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 41 cases where DVA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DVA's RSI Oscillator exited the oversold zone, of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DVA advanced for three days, in of 353 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved below the 0 level on September 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on DVA as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for DVA turned negative on September 10, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .
DVA moved below its 50-day moving average on August 25, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DVA crossed bearishly below the 50-day moving average on August 07, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DVA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: DVA's P/B Ratio (91.743) is very high in comparison to the industry average of (6.983). P/E Ratio (13.127) is within average values for comparable stocks, (116.264). Projected Growth (PEG Ratio) (1.510) is also within normal values, averaging (1.975). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (0.831) is also within normal values, averaging (1.574).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. DVA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a provider of integrated dialysis services for patients suffering from chronic kidney failure
Industry HospitalNursingManagement
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
UGOFX | 12.52 | N/A | N/A |
Victory Global Managed Volatility Instl | |||
NESYX | 65.37 | N/A | N/A |
Natixis US Equity Opportunities Y | |||
FSCNX | 17.04 | N/A | N/A |
Fidelity Advisor Asset Manager 60% C | |||
DRESX | 25.82 | N/A | N/A |
Driehaus Emerging Markets Small Cap Gr | |||
FAFGX | 87.65 | -0.14 | -0.16% |
American Funds Growth Fund of Amer 529F2 |
A.I.dvisor indicates that over the last year, DVA has been loosely correlated with DNTCF. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if DVA jumps, then DNTCF could also see price increases.
Ticker / NAME | Correlation To DVA | 1D Price Change % | ||
---|---|---|---|---|
DVA | 100% | -0.05% | ||
DNTCF - DVA | 43% Loosely correlated | -2.08% | ||
FMS - DVA | 43% Loosely correlated | -1.15% | ||
CHE - DVA | 41% Loosely correlated | -2.51% | ||
OPCH - DVA | 41% Loosely correlated | -3.03% | ||
HCA - DVA | 37% Loosely correlated | +0.57% | ||
More |
Ticker / NAME | Correlation To DVA | 1D Price Change % |
---|---|---|
DVA | 100% | -0.05% |
Hospital/Nursing Management industry (89 stocks) | 27% Poorly correlated | -0.84% |